Recursion Pharmaceuticals Overview
- Year Founded
-
2013

- Status
-
Public
- Employees
-
800

- Stock Symbol
-
RXRX

- Investments
-
5
- Share Price
-
$4.56
- (As of Friday Closing)
Recursion Pharmaceuticals General Information
Description
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.
Contact Information
Website
www.recursion.comCorporate Office
- 41 South Rio Grande Street
- Salt Lake City, UT 84101
- United States
Corporate Office
- 41 South Rio Grande Street
- Salt Lake City, UT 84101
- United States
Recursion Pharmaceuticals Timeline
Recursion Pharmaceuticals Stock Performance
As of 16-May-2025, Recursion Pharmaceuticals’s stock price is $4.56. Its current market cap is $1.85B with 406M shares.
(As of Friday Closing)
Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
---|---|---|---|---|---|---|
$4.56 | $4.25 | $3.79 - $12.36 | $1.85B | 406M | 24.1M | -$1.77 |
Recursion Pharmaceuticals Financials Summary
As of 31-Mar-2025, Recursion Pharmaceuticals has a trailing 12-month revenue of $59.8M.
In Thousands, USD |
TTM 31-Mar-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 |
---|---|---|---|---|
EV | 1,640,673 | 2,304,259 | 1,792,670 | 1,059,019 |
Revenue | 59,815 | 58,488 | 43,876 | 39,681 |
EBITDA | (542,044) | (441,874) | (326,745) | (233,919) |
Net Income | (574,775) | (463,661) | (328,066) | (239,476) |
Total Assets | 1,305,234 | 1,448,598 | 653,699 | 701,288 |
Total Debt | 92,910 | 108,492 | 50,672 | 51,005 |
Recursion Pharmaceuticals Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
Recursion Pharmaceuticals Cap Table
Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
---|
Recursion Pharmaceuticals Comparisons
Industry
Financing
Details
Recursion Pharmaceuticals Competitors (30)
One of Recursion Pharmaceuticals’s 30 competitors is Sygnature Discovery, a Private Equity-Backed company based in Nottingham, United Kingdom.
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Sygnature Discovery | Private Equity-Backed | Nottingham, United Kingdom | ||||
Twist Bioscience | Formerly VC-backed | South San Francisco, CA | ||||
Affimed | Formerly VC-backed | Mannheim, Germany | ||||
Inovio Pharmaceuticals | Corporation | Plymouth Meeting, PA | ||||
Verge Genomics | Venture Capital-Backed | South San Francisco, CA |
Recursion Pharmaceuticals Patents
Recursion Pharmaceuticals Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
US-12300360-B2 | Preemptible-based scaffold hopping | Active | 15-May-2024 | ||
US-12119090-B1 | Utilizing masked autoencoder generative models to extract microscopy representation autoencoder embeddings | Active | 19-Dec-2023 | ||
US-12119091-B1 | Utilizing masked autoencoder generative models to extract microscopy representation autoencoder embeddings | Active | 19-Dec-2023 | ||
US-20250157569-A1 | Utilizing compound-protein machine learning representations to generate bioactivity predictions | Pending | 09-Nov-2023 | ||
US-20250157595-A1 | Utilizing compound-protein machine learning representations to generate bioactivity predictions | Pending | 09-Nov-2023 | G16C20/70 |
Recursion Pharmaceuticals Signals
Recursion Pharmaceuticals Investors
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|
Recursion Pharmaceuticals Investments & Acquisitions (5)
Recursion Pharmaceuticals’s most recent deal was a Merger/Acquisition with Exscientia for . The deal was made on 20-Nov-2024.
Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
---|---|---|---|---|---|
Exscientia | 20-Nov-2024 | Merger/Acquisition | Drug Discovery | ||
Cyclica | 25-May-2023 | Merger/Acquisition | Discovery Tools (Healthcare) | ||
Valence Labs | 16-May-2023 | Merger/Acquisition | Drug Discovery | ||
Enveda | 22-Jun-2021 | Early Stage VC | Drug Discovery | ||
Vium | 28-Jul-2020 | Merger/Acquisition | Discovery Tools (Healthcare) |
Recursion Pharmaceuticals ESG
Risk Overview
Risk Rating
Updated March, 28, 2025
17.4 | Low Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,631
Rank
Percentile

Pharmaceuticals
Industry
of 843
Rank
Percentile

Biotechnology
Subindustry
of 365
Rank
Percentile

Recursion Pharmaceuticals Affiliates
Subsidiaries (4)
Name | Industry | Location | Year Founded |
---|---|---|---|
Valence Labs | Montreal, Canada | 2018 | |
Cyclica | Toronto, Canada | 2013 | |
Vium | San Mateo, CA | 2013 | |
Exscientia | Oxford, United Kingdom | 2012 |
Recursion Pharmaceuticals FAQs
-
When was Recursion Pharmaceuticals founded?
Recursion Pharmaceuticals was founded in 2013.
-
Where is Recursion Pharmaceuticals headquartered?
Recursion Pharmaceuticals is headquartered in Salt Lake City, UT.
-
What is the size of Recursion Pharmaceuticals?
Recursion Pharmaceuticals has 800 total employees.
-
What industry is Recursion Pharmaceuticals in?
Recursion Pharmaceuticals’s primary industry is Drug Discovery.
-
Is Recursion Pharmaceuticals a private or public company?
Recursion Pharmaceuticals is a Public company.
-
What is Recursion Pharmaceuticals’s stock symbol?
The ticker symbol for Recursion Pharmaceuticals is RXRX.
-
What is the current stock price of Recursion Pharmaceuticals?
As of 16-May-2025 the stock price of Recursion Pharmaceuticals is $4.56.
-
What is the current market cap of Recursion Pharmaceuticals?
The current market capitalization of Recursion Pharmaceuticals is $1.85B.
-
What is Recursion Pharmaceuticals’s current revenue?
The trailing twelve month revenue for Recursion Pharmaceuticals is $59.8M.
-
Who are Recursion Pharmaceuticals’s competitors?
Sygnature Discovery, Twist Bioscience, Affimed, Inovio Pharmaceuticals, and Verge Genomics are some of the 30 competitors of Recursion Pharmaceuticals.
-
What is Recursion Pharmaceuticals’s annual earnings per share (EPS)?
Recursion Pharmaceuticals’s EPS for 12 months was -$1.77.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »